Damage to articular cartilage, the tissue that allows for a smooth gliding of the articulating surface of a joint (and to withstand high loads), is an unsolved problem, especially following joint trauma [1]. As adult, hyaline cartilage is aneural, avascular, and without a lymphatic drainage, it does not have access to reparative cells that may be brought locally in response toinjury. Defects (partial or full-thickness) of the cartilage thus do not heal on themselves and instead, tend to become persistent and progress inevitably, often towards osteoarthritis [2].Current options for cartilage repair are diverse (marrow-stimulating techniques, transplantation of tissue or cells, replacement surgery), yet none can reliably regenerate thenatural functions of the cartilage, including its integrity (type-II and not type-I collagen), the adherence of the repair tissue to the surrounding cartilage, and the ability of withstanding mechanical stress over time.Considerable efforts have been made to improve the repair processes and in particular, the promise of treating cartilage defects by cell- and gene-based approaches has attracted much attention [3-7]. Indeed, administration of candidate genes, rather than recombinant factors with short half-lives, might be a means to promote sustained repair like for disorders showing a gradual progression. The development of strategies using the implantation of genetically modified mesenchymal stem cells (MSCs) as therapeutic platforms might prove beneficial to enhance cartilage repair during surgical procedures. As a matter of fact, MSCs might be better suited for this purpose than committed cells such as chondrocytes that require more invasive methods of extraction and tend to lose their phenotype upon culture. Also, MSCs have the ability to recapitulate lineage transitions originally involved in mesenchymal tissue formation (cartilage, bone, fat tissue), among which a potential for chondrogenesis [8-10]. MSCs further display critical tropic activities and demonstrate, interestingly, a broad panel of immunomodulatory properties. MSCs can be isolated from the bone marrow, bone, adipose tissue, muscle, synovium, periosteum, and perichondrium. It is important to note that genetic modification of such cells might also allow to overcome some of the limitations stillassociated with their use, like the large amount of cells needed for application